Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
出版年份 2022 全文链接
标题
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
作者
关键词
-
出版物
NATURE MEDICINE
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-05-10
DOI
10.1038/s41591-022-01800-8
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- CAR T cells in solid tumors: challenges and opportunities
- (2021) Faroogh Marofi et al. Stem Cell Research & Therapy
- FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18.2 positive gastric and gastro-oesophageal adenocarcinoma
- (2021) U. Sahin et al. ANNALS OF ONCOLOGY
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation (Part 3 – Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays)
- (2021) Bart Corsaro et al. Bioanalysis
- Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases
- (2021) Min Shi et al. BMC CANCER
- The Burden of Peritoneal Metastases from Gastric Cancer: A Systematic Review on the Incidence, Risk Factors and Survival
- (2021) Anouk Rijken et al. Journal of Clinical Medicine
- Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
- (2020) Michael D. Jain et al. BLOOD
- Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
- (2020) Talha Badar et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Engineering CAR-T Cells for Next-Generation Cancer Therapy
- (2020) Mihe Hong et al. CANCER CELL
- Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial
- (2020) Yang Liu et al. CYTOTHERAPY
- Considerations in the development and validation of real-time quantitative polymerase chain reaction and its application in regulated bioanalysis to characterize the cellular kinetics of CAR-T products in clinical studies
- (2020) Tong-yuan Yang et al. Bioanalysis
- Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
- (2019) Xianjie Jiang et al. Molecular Cancer
- Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma.
- (2019) Xianbao Zhan et al. JOURNAL OF CLINICAL ONCOLOGY
- A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
- (2019) O Türeci et al. ANNALS OF ONCOLOGY
- Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
- (2019) Jiali Cheng et al. Frontiers in Oncology
- Lauren Histologic Type Is the Most Important Factor Associated With Pattern of Recurrence Following Resection of Gastric Adenocarcinoma
- (2018) Jun H. Lee et al. ANNALS OF SURGERY
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- CAR T-Cell Therapy in Large B-Cell Lymphoma
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
- (2017) Frederick L. Locke et al. MOLECULAR THERAPY
- Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers
- (2017) Kaichao Feng et al. Protein & Cell
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
- (2016) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge
- (2015) Simon Pernot WORLD JOURNAL OF GASTROENTEROLOGY
- Standardization of Diagnostic Immunohistochemistry: Literature Review and Geisinger Experience
- (2014) Fan Lin et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Principles of Analytic Validation of Immunohistochemical Assays: Guideline From the College of American Pathologists Pathology and Laboratory Quality Center
- (2014) Patrick L. Fitzgibbons et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer
- (2014) Yasutsuna Sasaki et al. CANCER SCIENCE
- PD-1 induction through TCR activation is partially regulated by endogenous TGF-β
- (2014) Raja Rekik et al. Cellular & Molecular Immunology
- Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
- (2013) R Alvarez et al. BRITISH JOURNAL OF CANCER
- Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cellsin vitroin a TLR4-independent manner
- (2012) Tillmann Michels et al. Journal of Immunotoxicology
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now